Molecular Diagnostics Market

Europe Molecular Diagnostics Market by Products (Reagents, Instruments, and Others), Test Locations (Self-test, Point of Care, and Central Laboratories), Technology (Isothermal Nucleic Acid Amplification Technology, PCR, Multiplex PCR, In Situ Hybridization, Chips & Microarrays, Mass Spectrometry, Transcription-mediated Amplification, and Sequencing), Applications (Microbiology, Cardiovascular Disease, Pharmacogenomics, Infectious Diseases, Neurological Disease, and Others), and Geography (the UK, Germany, Italy, France, the Netherlands, and Rest of Europe) - Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1704
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 173
  • Format:
  • Pub. Date: Upcoming
  • Share:

The Europe molecular diagnostics market size is estimated to register a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of diabetes, chronic diseases, cardiovascular, and other uncommunicable diseases.

Europe Molecular Diagnostics Market key Takeaways

Molecular diagnostics refers to the techniques in which biological markers are analyzed and applied for diagnostic and treatment purposes of infectious diseases as well as chronic illness. Scientific testing by applying molecular biology helps to diagnose & monitor disorders, mitigate risk, identify patients-based treatments along with agricultural biosecurity to monitor crop disease and take corrective measures. As per the Health Protection Report 2019, more than 447,694 new sexually transmitted infection (STI) diagnoses were reported in England. Out of these, Chlamydia cases constituted nearly 218,095, which was around 49% of all new STI diagnoses, gonorrhea cases were 56,259 representing around 13%, first episode genital warts were 57,318 cases representing around 13%, and genital herpes were 33,867 around 8%.

The COVID-19 outbreak, as an infectious disease, which was started in Wuhan (China) in December 2019 has become global pandemic in matter of few weeks. The COVID-19 pandemic had a positive impact on the molecular diagnostics market due to the usage of molecular diagnostic techniques for novel corona virus testing. The number of tests and sales of reagents got affected due to the lockdowns caused by the pandemic globally. However, surge in demand for diagnostic kits for COVID-19 testing across the globe due to strict regulations such as mandatory use of testing for travelers using commercial flights present a key aspect for the market development. Regulatory authorities have formulated policies to speed up approval of diagnostic products in both developing and developed countries. Several competitors in the healthcare industry have invested a massive funding to develop rapid tests for the virus as it becomes a need of the hour, which is expected to lower the negative impact of the pandemic on their operational capabilities and sustain their revenues.

Market Trends, Drivers, Restraints, and Opportunities

  • Increasing infectious diseases and chronic illness such as cancer in developed and developing regions is anticipated to upsurge the market growth.
  • Rising demand for molecular diagnostics to diagnose various cancer and genetic diseases is projected to propel the market growth in the coming years.
  • Technological advancement and new products development by key market players to enhance the diagnostic methods and procedures are major factors for accelerating the market growth.
  • Expensive diagnosis instruments and high maintenance cost involved in molecular diagnostics that can only be afforded by large hospitals and laboratories, which adversely impact the market. This is expected to hinder the market expansion.
  • Lack of skilled workers and delaying in molecular diagnosis tests approvals from regulatory bodies in some developed countries are the main challenges hampering the market growth.
  • Demand for companion diagnostics is growing as these devices assist the healthcare providers to make informed decisions for patient-based treatment using appropriate therapy. This is projected to boost the market.

Scope of the Report

The report on the Europe molecular diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Europe Molecular Diagnostics Market -Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Products (Reagents, Instruments, and Others), Test Locations (Self-test, Point of Care, and Central Laboratories), Technology (Isothermal Nucleic Acid Amplification Technology, PCR, Multiplex PCR, In Situ Hybridization, Chips & Microarrays, Mass Spectrometry, Transcription-mediated Amplification, and Sequencing), Applications (Microbiology, Cardiovascular Disease, Pharmacogenomics, Infectious Diseases, Neurological Disease, and Others)

Geographical Scope

The UK, Germany, Italy, France, the Netherlands, and Rest of Europe

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Dako, Bayer AG; Abbott Laboratories; Alere, Inc.; Hologic, Inc. (Gen probe); Danaher Corporation; Sysmex Corp.; Becton, Dickinson and Co.; Novartis AG; Johnson and Johnson; Qiagen N.V.; Cephid; Roche Diagnostics; and bioMérieux SA

 

Market Segment Insights

Reagents segment is projected to expand substantially

On the basis of products, the market is segmented into instrument, reagents, and others. The reagents segment is projected to expand substantially in the market in the coming years owing to technological advancement in the diagnostic process to examine multiple diseases. The commonly used reagents include salts, formamide, SDS, dextran, and sulphate or heparin, to perform in-situ hybridization assays. Thus, the increasing demand for usage of techniques comprising fluorescence in situ hybridization present another key factor boosting the growth of the reagents segment.

Europe Molecular Diagnostics Market by products

Central Laboratories segment is anticipated to propel the market growth

Based on test Locations, the Europe molecular diagnostic market is segmented into self-test, point of care, and central laboratories. The central laboratories segment is anticipated to propel the market growth during the forecast period owing to the increasing number of trained professionals, higher patient footfall, and advanced facilities of laboratory. Moreover, the expansion of multiple clinical laboratory assays and easy availability of the advanced assays to perform molecular diagnosis of various illnesses are expected to boost the segment growth in the coming years.

On the other hand, the point of care segment is expected to upsurge at a considerable CAGR during the forecast period. Factors such as increasing demand for quick diagnosis, as well as the availability of newly developed PoC technology to monitor treatment reactions in patients having cardiac problem, are some key factors for driving segment growth.

PCR segment is anticipated to register a substantial growth rate

In terms of technology, the market is categorized as isothermal nucleic acid amplification technology, PCR, multiplex PCR, in situ hybridization, chips & microarrays, mass spectrometry, transcription-mediated amplification, and sequencing. The PCR segment is anticipated to register a substantial growth rate during the forecast period owing to rising adoption of the test for detecting infectious diseases especially the COVID virus. Moreover, wide application of the technology in molecular diagnostics research and study present another key factor boosting the segment growth.

Infectious disease segment is expected to register a large market share

Based on applications, the Europe molecular diagnostics market is segregated as microbiology, cardiovascular disease, pharmacogenomics, infectious diseases, neurological disease, and others. The infectious disease segment is expected to register a large market share during the forecast period due to the rising cases of infectious disease including HIV and other flu or viral diseases. Moreover, the improvement in diagnostics test for the detection of infectious disease is anticipated to boost the segment growth. Meanwhile, the cardiovascular disease segment is projected to hold a major share of the market in the coming years due to increasing prevalence of cardiac arrest and heart-related diseases especially in the developed countries. Increasing demand for early and efficient diagnosis for detection of heart disease is further projected to escalate the segment expansion.

Europe Molecular Diagnostics Market by applications

Germany is projected to dominate the market

In terms of regions, the Europe molecular diagnostics market is classified as the UK, Germany, Italy, France, the Netherlands, and Rest of Europe. Germany is projected to dominate the market, expanding at a rapid pace during the forecast period owing to rise in adoption of technological advancements in diagnostic kits and extensive research studies in the field of molecular diagnostics. The UK, being the second major country generating high market revenue, is expected to register a substantial growth rate in the market during the forecast period. The presence of well-developed healthcare infrastructure, increasing disposable income, and the rising awareness regarding the benefits for the early diagnosis of diseases including cancer and HIV especially in the UK and Germany are the key factors contributing towards the growth of the overall regional market.

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Molecular Diagnostics Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Molecular Diagnostics Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Molecular Diagnostics Market - Supply Chain
  4.5. Global Molecular Diagnostics Market Forecast
     4.5.1. Molecular Diagnostics Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Molecular Diagnostics Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Molecular Diagnostics Market Absolute $ Opportunity
5. Global Molecular Diagnostics Market Analysis and Forecast by Applications
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Applications
     5.2.2. Y-o-Y Growth Projections by Applications
  5.3. Molecular Diagnostics Market Size and Volume Forecast by Applications
     5.3.1. Microbiology
     5.3.2. Cardiovascular Disease
     5.3.3. Pharmacogenomics
     5.3.4. Infectious Diseases
     5.3.5. Neurological Disease
  5.4. Absolute $ Opportunity Assessment by Applications
  5.5. Market Attractiveness/Growth Potential Analysis by Applications
6. Global Molecular Diagnostics Market Analysis and Forecast by Region
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Region
     6.2.2. Y-o-Y Growth Projections by Region
  6.3. Molecular Diagnostics Market Size and Volume Forecast by Region
     6.3.1. North America
     6.3.2. Latin America
     6.3.3. Europe
     6.3.4. Asia Pacific
     6.3.5. Middle East and Africa (MEA)
  6.4. Absolute $ Opportunity Assessment by Region
  6.5. Market Attractiveness/Growth Potential Analysis by Region
  6.6. Global Molecular Diagnostics Demand Share Forecast, 2019-2026
7. North America Molecular Diagnostics Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
  7.2. North America Molecular Diagnostics Market Size and Volume Forecast by Country
     7.2.1. U.S.
     7.2.2. Canada
  7.3. Absolute $ Opportunity Assessment by Country
  7.4. North America Molecular Diagnostics Market Size and Volume Forecast by Applications
     7.4.1. Microbiology
     7.4.2. Cardiovascular Disease
     7.4.3. Pharmacogenomics
     7.4.4. Infectious Diseases
     7.4.5. Neurological Disease
  7.5. Basis Point Share (BPS) Analysis by Applications
  7.6. Y-o-Y Growth Projections by Applications
  7.7. Market Attractiveness/Growth Potential Analysis
     7.7.1. By Country
     7.7.2. By Product Type
     7.7.3. By Application
  7.8. North America Molecular Diagnostics Demand Share Forecast, 2019-2026
8. Latin America Molecular Diagnostics Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Latin America Average Pricing Analysis
  8.2. Latin America Molecular Diagnostics Market Size and Volume Forecast by Country
      8.2.1. Brazil
      8.2.2. Mexico
      8.2.3. Rest of Latin America
   8.3. Absolute $ Opportunity Assessment by Country
  8.4. Latin America Molecular Diagnostics Market Size and Volume Forecast by Applications
     8.4.1. Microbiology
     8.4.2. Cardiovascular Disease
     8.4.3. Pharmacogenomics
     8.4.4. Infectious Diseases
     8.4.5. Neurological Disease
  8.5. Basis Point Share (BPS) Analysis by Applications
  8.6. Y-o-Y Growth Projections by Applications
  8.7. Market Attractiveness/Growth Potential Analysis
     8.7.1. By Country
     8.7.2. By Product Type
     8.7.3. By Application
  8.8. Latin America Molecular Diagnostics Demand Share Forecast, 2019-2026
9. Europe Molecular Diagnostics Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Europe Average Pricing Analysis
  9.2. Europe Molecular Diagnostics Market Size and Volume Forecast by Country
     9.2.1. Germany
     9.2.2. France
     9.2.3. Italy
     9.2.4. U.K.
     9.2.5. Spain
     9.2.6. Russia
     9.2.7. Rest of Europe
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Europe Molecular Diagnostics Market Size and Volume Forecast by Applications
     9.4.1. Microbiology
     9.4.2. Cardiovascular Disease
     9.4.3. Pharmacogenomics
     9.4.4. Infectious Diseases
     9.4.5. Neurological Disease
  9.5. Basis Point Share (BPS) Analysis by Applications
  9.6. Y-o-Y Growth Projections by Applications
  9.7. Market Attractiveness/Growth Potential Analysis
     9.7.1. By Country
     9.7.2. By Product Type
     9.7.3. By Application
  9.8. Europe Molecular Diagnostics Demand Share Forecast, 2019-2026
10. Asia Pacific Molecular Diagnostics Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Asia Pacific Average Pricing Analysis
  10.2. Asia Pacific Molecular Diagnostics Market Size and Volume Forecast by Country
     10.2.1. China
     10.2.2. Japan
     10.2.3. South Korea
     10.2.4. India
     10.2.5. Australia
     10.2.6. Rest of Asia Pacific (APAC)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Asia Pacific Molecular Diagnostics Market Size and Volume Forecast by Applications
     10.4.1. Microbiology
     10.4.2. Cardiovascular Disease
     10.4.3. Pharmacogenomics
     10.4.4. Infectious Diseases
     10.4.5. Neurological Disease
  10.5. Basis Point Share (BPS) Analysis by Applications
  10.6. Y-o-Y Growth Projections by Applications
  10.7. Market Attractiveness/Growth Potential Analysis
     10.7.1. By Country
     10.7.2. By Product Type
     10.7.3. By Application
  10.8. Asia Pacific Molecular Diagnostics Demand Share Forecast, 2019-2026
11. Middle East & Africa Molecular Diagnostics Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Middle East & Africa Average Pricing Analysis
  11.2. Middle East & Africa Molecular Diagnostics Market Size and Volume Forecast by Country
     11.2.1. Saudi Arabia
     11.2.2. South Africa
     11.2.3. UAE
     11.2.4. Rest of Middle East & Africa (MEA)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Middle East & Africa Molecular Diagnostics Market Size and Volume Forecast by Applications
     11.4.1. Microbiology
     11.4.2. Cardiovascular Disease
     11.4.3. Pharmacogenomics
     11.4.4. Infectious Diseases
     11.4.5. Neurological Disease
  11.5. Basis Point Share (BPS) Analysis by Applications
  11.6. Y-o-Y Growth Projections by Applications
  11.7. Market Attractiveness/Growth Potential Analysis
     11.7.1. By Country
     11.7.2. By Product Type
     11.7.3. By Application
  11.8. Middle East & Africa Molecular Diagnostics Demand Share Forecast, 2019-2026
12. Competition Landscape
  12.1. Global Molecular Diagnostics Market: Market Share Analysis
  12.2. Molecular Diagnostics Distributors and Customers
  12.3. Molecular Diagnostics Market: Competitive Dashboard
  12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     12.4.1. Bio-Rad Laboratories, Inc.
     12.4.2. Siemens Healthcare GmbH
     12.4.3. Dako, Bayer AG
     12.4.4. Abbott Laboratories
     12.4.5. Alere, Inc.
     12.4.6. Hologic, Inc. (Gen probe)
     12.4.7. Danaher Corporation

Segments Covered in the Report
The Europe molecular diagnostic market has been segmented on the basis of

Products

  • Reagents
  • Instruments

Test Locations

  • Self-test
  • Point of Care
  • Central Laboratories

Technology

  • Isothermal Nucleic Acid Amplification Technology (INAAT)
  • PCR
  • Multiplex PCR
  • In Situ Hybridization
  • Chips & Microarrays
  • Mass Spectrometry
  • Transcription-mediated Amplification
  • Sequencing

Applications

  • Microbiology
  • Cardiovascular Disease
  • Pharmacogenomics
  • Infectious Diseases
  • Neurological Disease

Geography

  • The UK
  • Germany
  • Italy
  • France
  • The Netherlands
  • Rest of Europe

Key Players

  • Bio-Rad Laboratories, Inc.
  • Siemens Healthcare GmbH
  • Dako, Bayer AG
  • Abbott Laboratories
  • Alere, Inc.
  • Hologic, Inc. (Gen probe)
  • Danaher Corporation
  • Sysmex Corp.
  • Becton, Dickinson and Co.
  • Novartis AG
  • Johnson and Johnson
  • Qiagen N.V.
  • Cephid
  • Roche Diagnostics
  • BioMérieux SA

Some of the key players competing in the Europe molecular diagnostics market are Bio-Rad Laboratories, Inc.; Siemens Healthcare GmbH; Dako, Bayer AG; Abbott Laboratories; Alere, Inc.; Hologic, Inc. (Gen probe); Danaher Corporation; Sysmex Corp.; Becton, Dickinson and Co.; Novartis AG; Johnson and Johnson; Qiagen N.V.; Cephid; Roche Diagnostics; bioMérieux SA.

These major players are implementing various marketing strategies, such as capital investments, merger & acquisitions, and new product development to enhance their market position in the regional competition. For instance, In May 2020, Stratos Genomics was acquired by Roche Diagnostics (Roche) keeping its target to progress the development of nanopore technology and give access to Stratos Genomics unique chemistry, Sequencing by Expansion. On the other hand, ID PoC system was launched by Abbott Laboratories in March, 2020. Neisseria gonorrhea and Chlamydia trachomatis testing kits are two diagnostic methods offered by Roche for the treatment of two common sexually contagion diseases. The improved version of these rapid testing tools is further expected to fuel the overall market growth.

Europe Molecular Diagnostics Market  by key players

Buy Report